Trending...
- Vijay Tirathrai named Managing Director in Dubai, UAE
- Colbert Packaging Announces Startup Moxie Program for Students
- Private Autopsies Provide Families in Colorado with Answers and Closure
MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella.
Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. However, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company, subject to adjustments and additional shares issued in a concurrent private placement. Pieris pre-merger stockholders will also be issued a contingent value right (CVR) representing the right to receive payments from, among other sources, proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals.
More on Wisconsin Eagle
The transaction agreement unreasonably limits competing transactions by Pieris as it imposes a significant penalty if Pieris accepts a competing bid. Pieris insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Pieris' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Pieris common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/pieris-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. However, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company, subject to adjustments and additional shares issued in a concurrent private placement. Pieris pre-merger stockholders will also be issued a contingent value right (CVR) representing the right to receive payments from, among other sources, proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals.
More on Wisconsin Eagle
- TUHLULA DA VIRGO – The Rise of a Star
- SolMining announces $88 million in funding
- Top Edu-Tainment IP, Badanamu, enters children's mental health space, launching Healthy Kids Music Network
- Costa Oil Partners with Rick Ware Racing for NASCAR Cup Series Debut at Iowa Speedway
- DARA Abrams NYC Stories Art Experience at One Art Space
The transaction agreement unreasonably limits competing transactions by Pieris as it imposes a significant penalty if Pieris accepts a competing bid. Pieris insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Pieris' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Pieris common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/pieris-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
Filed Under: Business
0 Comments
Latest on Wisconsin Eagle
- Early Bird Registration Now Open for the Inaugural OpenSSL Conference 2025
- "Google AI and the Quiet War on Sovereignty: The Case of Aquitaine"
- Immigrant-Owned Businesses Across U.S. Face New SBA and Equipment Financing Barriers
- Best Selling Author David McKnight Joins Tom Hegna on the "Financial Freedom with Tom Hegna" Podcast
- Legendary N.W.A. CoFounder & Tech Visionary OG Arabian Prince Joins Tech Coast Venture Network Board
- Former Irvine Mayor Farrah Khan Joins Tech Coast Venture Network Board
- DT Digital Relaunches as Redouble Digital, Expanding from Freelance Operation to Full-Service E-commerce Marketing Agency
- TL International Group Ltd Terminates Franchise Agreement with Apollo Rent A Car
- TSWHZC Addresses Recent Malicious Reports and Reaffirms Commitment to Regulatory Compliance and User Protection
- Introducing Lick Scented Bath Oils: Transform Your Bath into a Luxurious Escape
- Free Printable Math Bingo Cards Released for Teachers, Parents, and Students
- Voices Across the Men's Health Network:
- Bent Danholm To Be Featured On Global Podcast Network In Live Interview
- AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
- Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
- Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
- "When The Call Hits Home" Podcast Dives Into First Responder Financial Wellness with Brian Box
- Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
- Rising Conservative Star Jordan Brace Emerges as Influential Political Voice with Elite Washington Connections
- Conservative Latinos for PA Shaping the Future of Hispanic Community, Guest State Treasurer Stacy Garrity